High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes

Thrombosis and Haemostasis

Volumn 90, Issue 5, 2003, Pages 787-795

  Fernando, Lawrence P ^a   Natesan, Snehlatha ^a   Joseph, Kusumam ^a   Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Astrocytes; Binding sites; Endothelial cells; Factor XII; High molecular weight kininogen

Indexed keywords

BLOOD CLOTTING FACTOR 12; CYTOKERATIN; GLOBULAR C1Q RECEPTOR PROTEIN; GLOBULAR PROTEIN; HIGH MOLECULAR WEIGHT KININOGEN; PREKALLIKREIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; ZINC ION;

ANTIGEN BINDING; ARTICLE; ASTROCYTE; BINDING AFFINITY; BINDING SITE; CELL CULTURE; CELL SURFACE; CELL TYPE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LUNG ENDOTHELIUM; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; UMBILICAL VEIN;

EID: 0242521719     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-04-0231     Document Type: Article

References (47)

1. Mandle R Jr, Colman RW, Kaplan AP. Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-83.
2. Thompson RE, Mandle RJ, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-80.
3. Kaplan AP, Joseph K, Shibayama Y, et al. Bradykinin formation-plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol 1998; 16: 403-29.
4. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985; 6: 161-4.
5. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1-46.
6. Marceau F. Kinin B1 receptors: A review. Immunopharmacology 1995; 30: 1-26.
7. Davis AJ, Perkins MN. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine induced mechanical hyperalgesia in the rat. Br J Pharmacol 1994; 113: 63-8.
8. Schmaier AH, Kuo A, Lundberg D, et al. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 1988; 263: 16327-33.
9. Van Iwaarden F, De Groot PG, Bouma BN. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 1988; 263: 4698-703.
10. Motta G, Rojkjaer R, Hasan AAK, et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation. Blood 1998; 91: 516-28.
11. Zhao Y, Qiu Q, Mahdi F, et al. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberatin and NO formation. Am J Physiol 2001; 280: H1821-29.
12. Joseph K, Ghebrehiwet B, Peerschke EIB, et al. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of CIq (gC1q-R). Proc Natl Acad Sci USA 1996; 93: 8552-57.
13. Herwald H, Dedio J, Kellner R, et al. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. J Biol Chem 1996; 271: 13040-47.
14. Joseph K, Ghebrehiwet B, Kaplan AP. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 1999; 92: 246-55.
15. Hasan AAK, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA. 1998; 95: 3615-20.
16. Colman RW, Pixley RA, Najamunnisa S, et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 4 of the urokinase receptor. J Clin. Invest 1997; 100: 1481-7.
17. Renne T, Dedio J, David G, et al. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation of endothelial cells. J Biol Chem 2000; 275: 33688-96.
18. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209.
19. Glenner, CG, Wong, CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochim Biophys Res Commun 1984; 120: 885-90.
20. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-9.
21. Shibayama Y, Joseph K, Nakazawa Y, Ghebreihiwet B, Peerschke EIB, Kaplan AP. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated β-Amyloid protein. Clin Immunol 1999; 90: 89-99.
22. Lesne S, Docagne F, Gabriel C, et al. Transforming growth factor-B1 potentiates Amyloid β generation in astrocytes and in transgenic mice. J Biol Chem 2003; 278: 18408-18.
23. Ban M, Yoneda K, Kitajima Y. Differentiation of eccrine poroma cells to cytokeratin 1- and 10-expressing cells, the intermediate layer cells of eccrine sweat duct, in the tumor cell nests. J Cutan Pathol 1997; 24: 246-8.
24. Jaffe EA. Culture of human endothelial cells. Transplant Proc 1980; 12: 49-53.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of the protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
26. Joseph K, Nakazawa Y, Bahou WF, et al. Platelet glycoprotein Ib: A zinc-dependent binding protein for the heavy chain of high molecular weight kininogen. Mol Med 1999; 5: 555-63.
27. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 1949; 51: 660-72.
28. Munson PJ, Rodbard D. Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107: 220-39.
29. Reddigari SR, Shibayama Y, Brunnee T, et al. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993; 268: 11982-7.
30. Mahdi F, Shariat-Madar Z, Todd III RF, et al. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001; 97: 2342-50.
31. Baird TR, Walsh PN. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation. J Biol Chem 2002; 277: 38462-67.
32. Kuna P, Kaplan AP, Reddigari SR. Human high molecular weight kininogen binds to human umbilical cord endothelial cells through its heavy chain. Blood 1990; 76: 426a.
33. Barnathan ES, Kuo A, Rosenfeld L, et al. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 1990; 265: 2865-72.
34. Hasan AAK, Cines DB, Herwald H, et al. Mapping the cell binding sites in high molecular weight kininogen domain 5. J Biol Chem 1995; 270: 19256-61.
35. Moreira CR, Schmaier AH, Mahdi F, et al. Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Letters 2002; 523: 167-70.
36. Motta G, Shariat-Madar Z, Mahdi F, et al. Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix. Thromb Haemost 2001; 86: 840-7.
37. Joseph K, Ghebrehiwet B, Kaplan AP. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clinical Immunol 1999; 92: 246-55.
38. Fernando LP, Fernando AN, Joseph K, Kaplan AP. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells. J Thromb Haemost (In Press).
39. Shariat-Madar Z, Mahdi F, Schmaier AH. Mapping binding domains of kininogens on endothelial cell cytokeratin 1. J Biol Chem 1999; 274: 7137-45.
40. Joseph K, Tholanikunnel BG, Ghebrehiwet B, et al. Interaction of high molecular weight kininogen binding proteins with each other. Thromb Haemost 2001; 86: 2093.
41. Salcedo R, Resau JH, Halverson D, et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000; 14: 2055-64.
42. Takahashi K, Uwabe Y, Sawasaki Y, et al. Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am J Physiol 1998; 275: I-47-54.
43. Mason JC, Yarwood H, Sugars K, et al. Human umbilical vein and dermal microvascular endothelial cells show heterogeneity in response to PKC activation. Am J Physiol 1997; 273: C1233-40.
44. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA. 2002; 99: 896-900.
45. Mandle RJJ, Kaplan AP. Hageman factor substrates II. Human plasma prekallikrein. Mechanism of activation by hageman factor and participation in hageman factor dependent fibrinolysis. J Biol Chem 1977; 252: 6097-104.
46. Rojkjaer R, Hasan AAK, Motta M, et al. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80: 74-81.
47. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002; 277: 17962-9.